Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Benzatropin

Common Name Tropine benzohydryl ether methanesulfonate, Benztropine methanesulfo-nate (See also Benzatropine Mesylate)... [Pg.160]

Antagonists of muscarinic acetylcholine receptors had widely been used since 1860 for the treatment of Parkinson s disease, prior to the discovery of l-DOPA. They block receptors that mediate the response to striatal cholinergic interneurons. The antiparkinsonian effects of drugs like benzatropine, trihexyphenidyl and biper-iden are moderate the resting tremor may sometimes respond in a favorable manner. The adverse effects, e.g., constipation, urinary retention, and mental confusion, may be troublesome, especially in the elderly. [Pg.166]

These include atropine, scopolamine (hyoscine), trihexyphenidyl (benzhexol) and benzatropine. They block central muscarinic receptors involved in various afferent pathways of the vomiting reflex (Fig. 1). They have been used to control motion sickness, emesis in Meniere s disease and postoperative vomiting. Currently, hyoscine is largely restricted to the treatment of motion sickness where it has a fast onset of action but a short duration (4-6 h). Administration of hyoscine by transdermal patch produces a prolonged, low-level release of the drug with minimal side effects. To control postoperative vomiting, it should be applied >8 h before emesis is anticipated. [Pg.462]

CgHisNO 120-29-6) see Benzatropine Clobenztropine Deptropine Homatropine Octatropine methylbromide Tropisetron... [Pg.2452]

Symptomatic treatment in parkinsonism for the purpose of restoring a dopaminergic-cholinergic balance in the corpus striatum. Antiparkinsonian agents, such as benzatropine (p. 188), readily penetrate the blood-brain barrier. At centrally equi-effective dosage, their peripheral effects are less marked than are those of atropine. [Pg.106]

Benzatropine (benztropine) (Figure 6.10) is an ether of tropine used as an antimuscarinic drug in the treatment of Parkinson s disease. It is able to inhibit dopamine reuptake, helping to correct the deficiency which is characteristic of Parkinsonism. [Pg.301]

Benztropine (Benz benzatropine C2 II25N0 MW 307.19 g/mol CAS-No 86-13-5 (3-endo)-3-(diphenylmethoxy)-8-methyl-8-azabicyclo[3.2.1]octane). [Pg.298]

CnH oN2 883-40-9) see Benzatropine Cefbuperazone Cefixime Cefoxitin t i.v-Cefprozil Cibenzoline Latamoxef (/LS, /f,S)-I,2-diphenyl-l- 4- 2-(dimethylamino)ethoxy] phenyl Jbutane-1,4-diol (CmH., NO, 141854-25-3) see Toremifenc (Z)-l,2-diphenyl-l-[4-(2-(dimcthylamino)ethoxy)phenyl -... [Pg.2369]

A report of three cases (126) has suggested that central cholinergic overactivity is implicated, and that atropine sulfate 3 mg/day or synthetic anticholinergic agents (such as benzatropine mesylate 4 mg/day) ameliorate withdrawal symptoms within a few hours. The authors suggested that this technique may be especially useful in patients in whom tricyclic antidepressants must be abruptly withdrawn because of allergic or idiosyncratic reactions. [Pg.16]

The incidence of delirium in elderly subjects (over 65 years old) taking lithium does not appear to be higher than in those who are taking valproate (233). Among 5360 subjects with a mood disorder who had taken lithium or valproate in the previous year, the incidence of delirium with valproate was very similar to that of lithium (4.1 versus 2.8 cases/100 person years HR = 1.36 95% Cl = 0.94, 1.97). Both of these rates were significantly lower than the rates observed with the anticholinergic drug benzatropine. [Pg.137]

There were no changes in lithium pharmacokinetics when risperidone was substituted open-label for another neuroleptic drug in 13 patients (634). On the other hand, an 81-year-old man had an acute dystonic reaction 4 days after lithium was added to a regimen of risperidone, valproic acid, and benzatropine (635). [Pg.160]

Olanzapine versus chlorpromazine In 103 previously treatment-resistant patients with schizophrenia were given a prospective 6-week trial of 10-40 mg/day of haloperidol 84 failed to respond and were randomly assigned to a double-blind, 8-week, fixed-dose trial of either olanzapine 25 mg/day alone (n = 42) or chlorpromazine 1200 mg/day plus benzatropine mesylate 4 mg/day (n = 39) (51). There was no significant... [Pg.192]

The possibility of fatal intestinal dilatation, although very rare, warrants careful evaluation of persistent complaints of constipation, particularly in patients who also have vomiting and abdominal pain, distension, or tenderness (518). Acute intestinal pseudo-obstruction (Ogilvie s syndrome) has been reported in a patient taking haloperidol plus benzatropine (519). [Pg.225]

A 64-year-old woman started to take oral haloperidol 0.5 mg tds, and 3 days later was given intravenous benzatropine 2 mg for dystonia plus a second dose 1 hour later because she had not responded to the first dose. Her dystonia improved, but she started to develop abdominal distension and discomfort, and within the next 3-4 hours her whole abdomen had become significantly distended. Haloperidol and benzatropine were withdrawn and she was treated with hydration, nasogastric suction, a rectal tube, and frequent change of position. With this conservative therapy, her abdominal distension resolved completely in 24 hour. [Pg.225]

A series of cases has been reported in which heat stroke occurred during hot weather, probably due to impaired heat adaptation in patients taking benzatropine and ethyl-benzatropine (544) this can occur with other anticholinergic and neuroleptic drugs as well. [Pg.227]

Acute extrapyramidal reactions occur more often after ingestion of high-potency drugs, such as haloperidol and fluphenazine these respond to parenteral benzatropine, but anticholinergic drugs should be used judiciously, so as not to worsen peripheral or central autonomic toxicity. Other serious, but less frequent, complications include paralytic ileus and hypothermia. Acute renal insufficiency has been very rarely reported, but is apparently reversible and can occur secondary to severe hypotension or other causes after acute ingestion (615). [Pg.232]

Benzatropine and ethylbenzatropine are particularly likely to interact additively with other drugs with both anticholinergic and antihistaminic activity, such as neuroleptic drugs complications such as hyperpyrexia, coma, and toxic psychosis have been reported several times when such combinations were used (626-628). [Pg.233]

Enuresis has been rarely associated with clozapine (0.23% of patients) (SEDA-19, 54) (191), and has been successfully treated with benzatropine in patients taking a variety of psychotropic medications (192). [Pg.274]

Thrombocytopenia, with a platelet count of 20 x 109/1, possibly associated with olanzapine and subsequently with benzatropine mesylate, has been reported in a 38-year-old woman (223). [Pg.316]

An 11-year-old boy developed acute dysuria and increased frequency accompanied by gross hematuria. He was taking fluoxetine, valproic acid, benzatropine, haloperidol, clonidine, trazodone, and nasal desmopressin. One week before presentation, risperidone had been introduced instead of haloperidol to improve behavioral control. The risperidone was discontinued and haloperidol resumed, and his symptoms resolved during the following week. [Pg.346]

Dystonia occurred in an 81-year-old man who took lithium in addition to risperidone 1 mg/day, valproic acid 2250 mg/day, and benzatropine 4 mg/day (249). [Pg.352]

In a randomized, Phase III, double-blind study, ziprasidone 80 mg/day and 160 mg was more effective than placebo in patients with acute exacerbations of schizophrenia or schizoaffective disorders (n = 302) (20). After 6 weeks, somnolence (19%) and akathisia (13%) were more frequent with ziprasidone 160 mg than with placebo (5 and 7% each). Benzatropine was required at some time during the study by 20% of the patients taking ziprasidone 80 mg/day, 25% of those taking ziprasidone 160 mg/day, and 13% of those taking placebo. The long-term safety of ziprasidone is unknown. [Pg.370]

Benzatropine can cause slight memory impairment, detectable if special studies of mental function are performed (SEDA-13,115) (SEDA-15,137). [Pg.654]


See other pages where Benzatropin is mentioned: [Pg.205]    [Pg.205]    [Pg.2369]    [Pg.185]    [Pg.426]    [Pg.480]    [Pg.387]    [Pg.287]    [Pg.205]    [Pg.189]    [Pg.64]    [Pg.196]    [Pg.233]    [Pg.305]    [Pg.329]    [Pg.445]    [Pg.654]   


SEARCH



Benzatropine

Benzatropine

Benzatropine 4- Fluphenazine

Benzatropine 4- Trihexyphenidyl

Benzatropine 4- Ziprasidone

Benzatropine Chlorpromazine

Benzatropine Fluoxetine

Benzatropine Haloperidol

Benzatropine mesilate

Benzatropine neuroleptic drugs

Procyclidine Benzatropine

© 2024 chempedia.info